Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02598453 · ClinicalTrials.gov registry record · Phase 4
PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia
A Phase 4 study of Postmenopausal Osteoporosis, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 4
- Development phase
- 545
- Enrollment target
- 20
- Study locations
NCT02598453: Completed Phase 4 study of Postmenopausal Osteoporosis, sponsored by Hoffmann-La Roche.
NCT02598453 is a Phase 4 study of Postmenopausal Osteoporosis that has completed, run by Hoffmann-La Roche. The registered enrollment target is 545 participants, above the 482-participant average among 14 other Postmenopausal Osteoporosis trials with a reported enrollment target (13% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02598453, a Phase 4 study of Postmenopausal Osteoporosis, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 545 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate treatment adherence to different regimens of ibandronate in postmenopausal women with osteoporosis or osteopenia who are intolerant to daily or weekly alendronate or risedronate therapy due to gastrointestinal (GI) side effects. The anticipated time on study treatment is 12 months, and the target sample size is 517 individuals.
Conditions Studied
Interventions
- DRUG Ibandronate
Study Locations (20)
Florida
- - Beverly Hills
- - Fort Myers
- - Gainesville
- - Miami
- - Ocala
- - Palm Harbor
- - West Palm Beach
California
- - San Diego
- - San Diego
- - Santa Monica
- - Tacoma
- - Vista
Arizona
- - Lake Havasu City
- - Paradise Valley
Alabama
- - Montgomery
Arkansas
- - Pine Bluff
Georgia
- - Augusta
Idaho
- - Coeur d'Alene
Illinois
- - Champaign
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 545 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-09 |
| Phase | Phase 4 |
What the finished NCT02598453 record still lists
NCT02598453 is an interventional study that assigns participants to a tested intervention. The registered 545 participants enrollment target is mid-sized for trials with a published cap, above the 482-participant average among 14 other Postmenopausal Osteoporosis trials with a reported enrollment target (13% higher).
The record links to 1 condition, with Postmenopausal Osteoporosis appearing as the primary indexed condition, and to 1 intervention - of which Ibandronate is the first listed.
NCT02598453 names 20 study sites across 9 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT02598453 about?
NCT02598453 is a clinical study titled "PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia". The purpose of this study is to evaluate treatment adherence to different regimens of ibandronate in postmenopausal women with osteoporosis or osteopenia who are intolerant to daily or weekly alendronate or risedronate therapy due to gastrointestinal (GI) side effects. The anticipated time on study ...
What is the current status of trial NCT02598453?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 545 participants. The study started on 2005-01. Estimated completion is 2006-09.
What conditions does trial NCT02598453 study?
This clinical trial studies the following conditions: Postmenopausal Osteoporosis.
What interventions are being tested in trial NCT02598453?
The interventions under investigation include: Ibandronate (DRUG).
Who is sponsoring clinical trial NCT02598453?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02598453 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postmenopausal Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02598453's enrollment target sits among peer trials
545 4th of 14 higher than 11 of 14 other Postmenopausal Osteoporosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Postmenopausal Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anabolic Therapy in Postmenopausal Osteoporosis
ACTIVE NOT RECRUITING · Phase 4
-
A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
COMPLETED · Phase 4
-
A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)
COMPLETED · Phase 4
-
Dried Plums and Bone Health in Postmenopausal Women
ACTIVE NOT RECRUITING · NA
-
A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04553523 · 545 participants · NA
Hydrus® Microstent New Enrollment Post-Approval Study
- NCT03572374 · 546 participants · NA
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
- NCT05937685 · 546 participants · NA
Reducing Blood Pressure in Patients With High Cardiovascular Risk
- NCT06416150 · 546 participants · NA
Reducing Urban Cervical Cancer Disparities
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia